PTC Therapeutics (FRA:BH3) Research & Development: €384.2 Mil (TTM As of Mar. 2026)


FRA:BH3 PTC Therapeutics Inc FRA:BH3
51 GF Score
Price €72.26
GF Value €30.17
! 9 Warning Signs
View Full Analysis

What is PTC Therapeutics Research & Development?

PTC Therapeutics FRA:BH3 +0.36% 51 Research & Development is €384.2 Mil as of Mar. 2026. GuruFocus rates FRA:BH3 with a GF Score™ of 51/100 and a GF Value™ of €30.17. The stock has 9 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. PTC Therapeutics's Research & Development for the three months ended in Mar. 2026 was €87.3 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €384.2 Mil.

PTC Therapeutics  (FRA:BH3) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

PTC Therapeutics Research & Development Related Terms

PTC Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for PTC Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PTC Therapeutics Research & Development Chart

PTC Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 478.51 615.01 611.24 510.43 388.78

PTC Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 100.80 97.96 85.34 113.69 87.26
FRA:BH3
51GF Score
PTC Therapeutics Inc FRA:BH3
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PTC Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €384.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €384.2 Mil mean?
PTC Therapeutics (FRA:BH3) has a Research & Development of €384.2 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on PTC Therapeutics and its competitors.
Is PTC Therapeutics' Research & Development too high?
PTC Therapeutics' current Research & Development is €384.2 Mil. Overall, PTC Therapeutics has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does PTC Therapeutics' Research & Development compare to APGE and MIRM?
PTC Therapeutics' Research & Development of €384.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on PTC Therapeutics and its competitors. PTC Therapeutics's current Research & Development is €384.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PTC Therapeutics stock overvalued right now?
PTC Therapeutics (FRA:BH3) has a current Research & Development of €384.2 Mil. The stock's GF Value™ is €30.17, compared to a current price of €72.26 — trading 139.5% above its estimated fair value. The current Research & Development is €384.2 Mil. PTC Therapeutics' overall GF Score™ is 51/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For PTC Therapeutics (FRA:BH3), the current Research & Development is €384.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PTC Therapeutics (FRA:BH3) Overvalued in 2026?

Based on GuruFocus' analysis, PTC Therapeutics stock appears to be overvalued. The current stock price of €72.26 is trading 139.5% above its estimated GF Value™ of €30.17.

Key valuation signals for FRA:BH3:

  • Research & Development: €384.2 Mil
  • GF Value™: €30.17 vs. price of €72.26 (139.5% above fair value)
  • GF Score™: 51/100 with 9 warning signs

No single metric tells the full story. See the FRA:BH3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PTC Therapeutics Business Description

Other Exchanges PTCT:USABH3:Germany
Address 500 Warren Corporate Center Drive, Warren, NJ, USA, 07059
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
51GF Score

Get the complete analysis for FRA:BH3

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€72.26
Price
€30.17
GF Value